RG retweeted
$WMT | Walmart Q3 2026 Earnings
- Adj EPS: 65c (est 64c)
- Rev: $188.84B (est $187.17B)
- Walmart-Only US Stores Comp Sales Ex-Gas: +2.9%
- Sam's Club US Comp Sales Ex-Gas: +4.9% (est +4.63%)
- Sees FY Adjusted EPS: $2.84 To $2.89 (Saw $2.80 To $2.87)
RG retweeted
BREAKING: Anthropic, $ANT, is expected to begin trading on the Nasdaq today at 10:00 AM ET, with shares being released for quotation at 9:50 AM ET.
The IPO is expected to raise $81.3 billion, making it the largest IPO in history.
Shares were priced at $83 each, valuing the company at $1.5 trillion.
RG retweeted
Nice looking beat & raise for $PANW.
Next-gen ARR & revenue ahead. Profit ahead.
Q2 guidance ahead. Annual guidance raised.
Every enterprise software investor feel free to say "thank you, Nikesh."
RG retweeted
The nuclear power buildout is gaining pace ☢️🌍
Construction started on eight reactors in the first half of 2026, marking one of the highest levels for that period in 40 year, according to the IEA
In total, almost 90GW of capacity is under construction around the world
Contributing factor why $NVDA likely stays range bound for the foreseeable future
2
91
RG retweeted
$TGT | Target Q3 2026 Earnings
- Net Sales: $27.07B (est $26.53B)
- Adj EPS: $2.65 (est $2.08)
- Gross Margin: 30.5% vs 28.2% Y/Y
- Sees FY Net Sales Growth: Around 6%
- Sees FY Oper Income Margin Rate: Around 6.2%
- Sees FY Adj EPS: $10.65 To $11.40 (prev $9.90 To $10.90)
RG retweeted
$NVDA | Nvidia Q3 27 Earnings:
• Rev: $115.8B (est $109.33B)
• Adj EPS: $2.68 (est $2.47)
• Data Centre Rev: $107.6B (est $101.87B)
• Compute & Networking Rev: $106.0B (est $98.27B)
• Edge Computing Rev: $8.2B (est $7.5B)
• Graphics Rev: $9.8B (est $8.84B)
• Sees Q4 Rev: $127.4B To $132.6B (est $125.25B)
• Sees Q4 Adj Gross Margin: 71% To 72%
• Sees Q4 Adj Oper Expenses: Around $10.7B (est $9.99B)
• Board Approves Additional $150B Share Buyback In Sep
RG retweeted
Europe Has Already Drained 10% Of Its Summer Gas Injections zerohedge.com/energy/europe-…
RG retweeted
$SLS +300% (Market cap: ~$6B)
Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint.
Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in patients with acute myeloid leukemia (AML), with a statistically significant hazard ratio of 0.59 (p=0.035).
Median overall survival:
• GPS vaccine: 24.0 months
• Best available treatment: 14.7 months
That's a 9.3-month improvement in median survival.
The 126-patient REGAL trial focused on AML patients in their second or later remission who were unable to undergo a stem cell transplant, a group with limited treatment options.
Licensed from Memorial Sloan Kettering, GPS is designed to stimulate the immune system to target residual leukemia cells expressing the WT1 protein.
The vaccine was generally well tolerated, with mostly mild to moderate side effects, primarily injection-site reactions. No new safety concerns were identified.
Sellas now plans to meet with the FDA to discuss an accelerated filing strategy, targeting a submission for approval in the first half of 2027.
Full secondary endpoint results are still pending, and the vaccine remains investigational.
RG retweeted
$DIS | Disney Q4 2026 Earnings
- Adj EPS: $1.77 (est $1.66)
- Rev: $25.95B (est $25.18B)
- Sees FY27 Capex: About $9B (est $8.87B)
- Sees Q1 FY27 Total Segment Oper Income: About $5.4B
- Declares Cash Dividend Of $2.00/Share, To Be Paid In Two Instalments Of $1.00/Share
Guyana now has 1.1 MMbpd of installed capacity. @exxonmobil has started production at Uaru, its fifth Stabroek development, with the Errea Wittu FPSO set to reach 250,000 bpd in early 2027. #Guyana #FPSO #Deepwater #ExxonMobil
worldoil.com/news/2026/11/16…





















